Progenics Pharmaceuticals (PGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 34,986 | 15,622 | 11,698 | 69,429 | 8,676 |
| Cost of Goods | 3,168 | 0 | 0 | N/A | N/A |
| Gross Profit | 31,818 | 15,622 | 11,698 | 69,429 | 8,676 |
| Operating Expenses | 98,145 | 81,978 | 70,098 | 56,325 | 47,980 |
| Operating Income | -66,159 | -66,356 | -58,400 | 13,104 | -39,304 |
| Interest Expense | 2,376 | 2,933 | 4,285 | 527 | 0 |
| Other Income | 0 | 0 | 0 | 0 | 52 |
| Pre-tax Income | -68,535 | -69,289 | -62,685 | 12,577 | -39,252 |
| Income Tax | 17 | -1,632 | -11,672 | 1,844 | -133 |
| Net Income Continuous | -68,552 | -67,657 | -51,013 | 10,733 | -39,119 |
| Minority Interests | N/A | N/A | N/A | -73 | -7 |
| Net Income | $-68,552 | $-67,657 | $-51,013 | $10,806 | $-39,112 |
| EPS Basic Total Ops | -0.80 | -0.87 | -0.73 | 0.15 | -0.56 |
| EPS Basic Continuous Ops | -0.80 | -0.87 | -0.73 | 0.15 | -0.56 |
| EPS Diluted Total Ops | -0.80 | -0.87 | -0.73 | 0.15 | -0.56 |
| EPS Diluted Continuous Ops | -0.80 | -0.87 | -0.73 | 0.15 | -0.56 |
| EPS Diluted Before Non-Recurring Items | -0.80 | -0.63 | -0.90 | 0.15 | -0.56 |
| EBITDA(a) | $-63,793 | $-41,659 | $-57,279 | $15,182 | $-38,739 |